{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:15:15Z","timestamp":1782422115308,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"National Institute of Allergy and Infectious Diseases (US)","award":["# K23AI089259"],"award-info":[{"award-number":["# K23AI089259"]}]},{"name":"National Institute of Allergy and Infectious Diseases (US)","award":["U01AI089244"],"award-info":[{"award-number":["U01AI089244"]}]},{"name":"National Center for Advancing Translational Sciences (US)","award":["UL1TR000114"],"award-info":[{"award-number":["UL1TR000114"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2325-9","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T11:50:42Z","timestamp":1490269842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda"],"prefix":"10.1186","volume":"17","author":[{"given":"Anu","family":"Ramachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Rajasingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maunank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"issue":"4","key":"2325_CR1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","volume":"23","author":"BJ Park","year":"2009","unstructured":"Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. AIDS. 2009;23(4):525\u201330.","journal-title":"AIDS"},{"issue":"7","key":"2325_CR2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00002030-200205030-00009","volume":"16","author":"N French","year":"2002","unstructured":"French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16(7):1031\u20138.","journal-title":"AIDS"},{"issue":"4","key":"2325_CR3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ije\/27.4.698","volume":"27","author":"M Okongo","year":"1998","unstructured":"Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol. 1998;27(4):698\u2013702.","journal-title":"Int J Epidemiol"},{"issue":"9","key":"2325_CR4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/339540","volume":"34","author":"EL Corbett","year":"2002","unstructured":"Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis. 2002;34(9):1251\u20138.","journal-title":"Clin Infect Dis"},{"key":"2325_CR5","unstructured":"WHO U. Towards Universal Access: Scaling up priority HIV\/AIDS interventions in the health sector. Progress Report. World Health Organization. 2011; 53. Available at: http:\/\/www.who.int\/hiv\/topics\/treatment\/data\/en\/index2.html . Accessed 14 Jan 2015."},{"issue":"16","key":"2325_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1097\/QAD.0b013e3282a4a64d","volume":"21","author":"JN Jarvis","year":"2007","unstructured":"Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS. 2007;21(16):2119\u201329. doi: 10.1097\/QAD.0b013e3282a4a64d .","journal-title":"AIDS"},{"issue":"3","key":"2325_CR7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11904-013-0165-9","volume":"10","author":"AC Meyer","year":"2013","unstructured":"Meyer AC, Jacobson M. Asymptomatic cryptococcemia in resource-limited settings. Curr HIV\/AIDS Rep. 2013;10(3):254\u201363.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"2325_CR8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/587667","volume":"46","author":"A Kambugu","year":"2008","unstructured":"Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694\u2013701.","journal-title":"Clin Infect Dis"},{"key":"2325_CR9","doi-asserted-by":"crossref","unstructured":"Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev. 2005;2005(3):CD004773.","DOI":"10.1002\/14651858.CD004773.pub2"},{"issue":"12","key":"2325_CR10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1473-3099(11)70245-6","volume":"11","author":"R Parkes-Ratanshi","year":"2011","unstructured":"Parkes-Ratanshi R, Wakeham K, Levin J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11(12):933\u201341.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2325_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/cid\/cir379","volume":"53","author":"MD Lindsley","year":"2011","unstructured":"Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321\u20135.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2325_CR12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1128\/CVI.00446-12","volume":"19","author":"MJ Binnicker","year":"2012","unstructured":"Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19(12):1988\u201390.","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"2325_CR13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/CVI.00536-12","volume":"20","author":"J Hansen","year":"2013","unstructured":"Hansen J, Slechta ES, Gates-Hollingsworth MA, et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol. 2013;20(1):52\u20135.","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"2325_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049541","volume":"7","author":"BJ McMullan","year":"2012","unstructured":"McMullan BJ, Halliday C, Sorrell TC, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One. 2012;7(11):e49541.","journal-title":"PLoS One"},{"issue":"1","key":"2325_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3201\/eid2001.130906","volume":"20","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20(1):45\u201353.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"2325_CR16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/cid\/cir613","volume":"53","author":"JN Jarvis","year":"2011","unstructured":"Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53(10):1019\u201323.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2325_CR17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/13693786.2013.781692","volume":"51","author":"P Escandon","year":"2013","unstructured":"Escandon P, Lizarazo J, Agudelo CI, Chiller T, Castaneda E. Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia. Med Mycol. 2013;51(7):765\u20138.","journal-title":"Med Mycol"},{"issue":"3","key":"2325_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/17530059.2012.681300","volume":"6","author":"TR Kozel","year":"2012","unstructured":"Kozel TR, Bauman SK. CrAg lateral flow assay for cryptococcosis. Expert Opin Med Diagn. 2012;6(3):245\u201351.","journal-title":"Expert Opin Med Diagn"},{"issue":"27","key":"2325_CR19","first-page":"585","volume":"63","author":"J McKenney","year":"2014","unstructured":"McKenney J, Smith RM, Chiller TM, et al. Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012. MMWR Morb Mortal Wkly Rep. 2014;63(27):585\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2325_CR20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-3156.2007.01874.x","volume":"12","author":"CA Liechty","year":"2007","unstructured":"Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12(8):929\u201335.","journal-title":"Trop Med Int Health"},{"issue":"7","key":"2325_CR21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/597262","volume":"48","author":"JN Jarvis","year":"2009","unstructured":"Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48(7):856\u201362.","journal-title":"Clin Infect Dis"},{"key":"2325_CR22","doi-asserted-by":"crossref","first-page":"18821","DOI":"10.7448\/IAS.17.1.18821","volume":"17","author":"AR Ganiem","year":"2014","unstructured":"Ganiem AR, Indrati AR, Wisaksana R, et al. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia. J Int AIDS Soc. 2014;17:18821.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"2325_CR23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/clinids\/23.4.827","volume":"23","author":"M Feldmesser","year":"1996","unstructured":"Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis. 1996;23(4):827\u201330.","journal-title":"Clin Infect Dis"},{"key":"2325_CR24","volume-title":"Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children","author":"WHO","year":"2011","unstructured":"WHO. Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. 2011."},{"key":"2325_CR25","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","volume":"385","author":"S Mfinanga","year":"2015","unstructured":"Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385:2173\u201382.","journal-title":"Lancet"},{"key":"2325_CR26","unstructured":"Pac L, Horwitz M, Namutembi A. Integrated Pre-Antiretroviral Therapy Screening and Treatment for Tuberculosis and Cryptococcal Antigenemia. JAIDS. 2015. (in press)."},{"issue":"7","key":"2325_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069288","volume":"8","author":"JN Jarvis","year":"2013","unstructured":"Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One. 2013;8(7):e69288.","journal-title":"PLoS One"},{"issue":"2","key":"2325_CR28","first-page":"e37","volume":"72","author":"S Vallabhaneni","year":"2016","unstructured":"Vallabhaneni S, et al. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa. JAIDS. 2016;72(2):e37\u201342.","journal-title":"JAIDS"},{"issue":"5","key":"2325_CR29","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/QAI.0000000000000527","volume":"68","author":"L Pac","year":"2015","unstructured":"Pac L, Horwitz MM, Namutebi AM, Auerbach BJ, Semeere A, Namulema T, et al. Implementation and operational research: integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia. J Acquir Immune Defic Syndr. 2015;68(5):e69\u201376.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"26","key":"2325_CR30","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","volume":"370","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"12","key":"2325_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051291","volume":"7","author":"EK Butler","year":"2012","unstructured":"Butler EK, Boulware DR, Bohjanen PR, Meya DB. Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One. 2012;7(12):e51291.","journal-title":"PLoS One"},{"issue":"6","key":"2325_CR32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jinf.2010.03.015","volume":"60","author":"P Pongsai","year":"2010","unstructured":"Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect. 2010;60(6):474\u20137.","journal-title":"J Infect"},{"issue":"4","key":"2325_CR33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/tmi.12067","volume":"18","author":"AC Meyer","year":"2013","unstructured":"Meyer AC, Kendi CK, Penner JA, et al. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health. 2013;18(4):495\u2013503.","journal-title":"Trop Med Int Health"},{"key":"2325_CR34","unstructured":"UNAIDS. \"The HIV\/AIDS Uganda Country Progress Report 2014\" http:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/UGA_narrative_report_2015.pdf . Accessed 14 May 2016"},{"key":"2325_CR35","unstructured":"Joint Medical Store. Catalogue and Price Indicator. http:\/\/www.jms.co.ug\/sites\/default\/files\/resources\/Catalogue%20Feb%202015_light%20version_0.pdf . Accessed 4 Mar 2016."},{"issue":"2","key":"2325_CR36","first-page":"44","volume":"2","author":"A Ninci","year":"2004","unstructured":"Ninci A, Ocakacon R. How Much Do Lab Tests Cost? Analysis of Lacor Hospital Laboratory Services. Health Policy Dev. 2004;2(2):44\u2013150.","journal-title":"Health Policy Dev"},{"issue":"5","key":"2325_CR37","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/QAI.0b013e31824c837e","volume":"59","author":"R Rajasingham","year":"2012","unstructured":"Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59(5):e85\u201391.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"2325_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001316","volume":"9","author":"R Rajasingham","year":"2012","unstructured":"Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2012;9(9):e1001316.","journal-title":"PLoS Med"},{"key":"2325_CR39","unstructured":"Moreland S, Namisango E, Paxton A, Powell R. Measure Evaluation - The costs of HIV treatment, care, and support services in Uganda: a technical report. 2013."},{"issue":"15","key":"2325_CR40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253\u20138.","journal-title":"JAMA"},{"issue":"4","key":"2325_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-155-4-201108160-00358","volume":"155","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209\u201316.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2325_CR42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","volume":"20","author":"RA Hirth","year":"2000","unstructured":"Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332\u201342.","journal-title":"Med Decis Making"},{"key":"2325_CR43","unstructured":"WHO. Cost-Effectiveness Thresholds. Available at: http:\/\/www.who.int\/choice\/costs\/CER_levels\/en\/ . Accessed 4 Nov 2014."},{"key":"2325_CR44","unstructured":"World_Bank. GDP per capita by country.Available at: http:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?order=wbapi_data_value_2013+wbapi_data_value+wbapi_data_value-last&sort=asc . Accessed 4 Nov 2014."},{"key":"2325_CR45","unstructured":"Fiani D, Vedastus A, Neborak J et al. Maximizing detection and improving outcomes of cryptococcosis in rural Tanzania. 2016. Available at: http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2016\/760_0.pdf Accessed 14 Jun 2016"},{"key":"2325_CR46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/hiv.12245","volume":"16","author":"N Govender","year":"2015","unstructured":"Govender N, Roy M, Mendes J, Zulu T, Chiller T, Karstaedt A. Evaluation of Screening and Treatment of Cryptococcal Antigenaemia among HIV-infected Persons in Soweto, South Africa. HIV Med. 2015;16:468\u201376.","journal-title":"HIV Med"},{"issue":"1","key":"2325_CR47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jinf.2012.09.014","volume":"66","author":"S Patel","year":"2013","unstructured":"Patel S, Shin GY, Wijewardana I, et al. The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. J Infect. 2013;66(1):75\u20139.","journal-title":"J Infect"},{"key":"2325_CR48","doi-asserted-by":"crossref","unstructured":"McKenney J, Bauman S, Neary B, et al. Prevalence, Correlates, and Outcomes o Cryptococcal Antigen Positivity Among Patients With AIDS, United States, 1986\u20132012. Clin Infect Dis. 2015;60(6):959\u201365.","DOI":"10.1093\/cid\/ciu937"},{"key":"2325_CR49","doi-asserted-by":"crossref","first-page":"c6218","DOI":"10.1136\/bmj.c6218","volume":"341","author":"E Bendavid","year":"2010","unstructured":"Bendavid E, Leroux E, Bhattacharya J, Smith N, Miller G. The relation of price of antiretroviral drugs and foreign assistance with coverage of HIV treatment in Africa: retrospective study. BMJ. 2010;341:c6218.","journal-title":"BMJ"},{"issue":"12","key":"2325_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143433","volume":"10","author":"V Jain","year":"2015","unstructured":"Jain V, Chang W, Byonanebye DM, et al. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells\/uL in Rural Uganda. PLoS One. 2015;10(12):e0143433. doi: 10.1371\/journal.pone.0143433 . Lima VD, ed","journal-title":"PLoS One"},{"issue":"4","key":"2325_CR51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/655143","volume":"51","author":"DB Meya","year":"2010","unstructured":"Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells\/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448\u201355.","journal-title":"Clin Infect Dis"},{"key":"2325_CR52","unstructured":"WHO. Age-Specific Disability Weights for untreated and treated forms of sequelae included in the Global Burden of Disease Study. http:\/\/www.who.int\/healthinfo\/bodreferencedisabilityweights.xls . Accessed Jun 10, 2014."},{"issue":"9859","key":"2325_CR53","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129\u201343.","journal-title":"Lancet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T23:35:42Z","timestamp":1568936142000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2325-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]},"article-number":"225"}}